Adam Rosenberg
Director/Board Member at ELIEM THERAPEUTICS, INC.
Net worth: 487 994 $ as of 31/03/2024
Profile
Adam J.
Rosenberg was the founder of Link Medicine Corp.
(founded in 2005) where he served as the Chief Executive Officer from 2005 to 2009.
He is also the founder of Teleos Therapeutics LLC.
Mr. Rosenberg's current job(s) include being the Chairman of Ambagon Therapeutics, Inc., an Independent Director at Eliem Therapeutics, Inc., a Director at Sionna Therapeutics, Inc., an Advisor at Atlas Venture Advisors, Inc., and a Venture Partner at RA Capital Management LP (Private Equity).
Mr. Rosenberg's former job includes being the President, Chief Executive Officer & Director of Rodin Therapeutics, Inc. In terms of education, Mr. Rosenberg is a graduate of the University of Virginia and holds an undergraduate degree from Whittier College.
Mr. Rosenberg is also the founder of Teleos Therapeutics LLC.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ELIEM THERAPEUTICS, INC.
0.65% | 18/05/2023 | 178,100 ( 0.65% ) | 487 994 $ | 31/03/2024 |
Adam Rosenberg active positions
| Companies | Position | Start |
|---|---|---|
| ELIEM THERAPEUTICS, INC. | Director/Board Member | 01/10/2020 |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | Director/Board Member | - |
Ambagon Therapeutics, Inc.
 Ambagon Therapeutics, Inc. BiotechnologyHealth Technology Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA. | Chairman | - |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | - |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Private Equity Investor | 01/01/2020 |
Former positions of Adam Rosenberg
| Companies | Position | End |
|---|---|---|
Link Medicine Corp.
 Link Medicine Corp. Pharmaceuticals: MajorHealth Technology Link Medicine Corp. develops disease modifying neurodegenerative therapies. The company was founded by Edward I. Rudman, Peter T. Lansbury, David Neafus and Adam J. Rosenberg in 2005 and is headquartered in Cambridge, MA. | Chief Executive Officer | 01/01/2009 |
| Teleos Therapeutics LLC | Chief Executive Officer | - |
Rodin Therapeutics, Inc.
 Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | Chief Executive Officer | - |
Training of Adam Rosenberg
| University of Virginia | Graduate Degree |
| Whittier College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ELIEM THERAPEUTICS, INC. | Health Technology |
| Private companies | 7 |
|---|---|
Link Medicine Corp.
Link Medicine Corp. Pharmaceuticals: MajorHealth Technology Link Medicine Corp. develops disease modifying neurodegenerative therapies. The company was founded by Edward I. Rudman, Peter T. Lansbury, David Neafus and Adam J. Rosenberg in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Rodin Therapeutics, Inc.
Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | Health Technology |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Finance |
Ambagon Therapeutics, Inc.
Ambagon Therapeutics, Inc. BiotechnologyHealth Technology Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA. | Health Technology |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | Health Services |
| Teleos Therapeutics LLC |
- Stock Market
- Insiders
- Adam Rosenberg
